Full-Time

Director – HR Business Partner

Therapeutics & R&D

Posted on 5/11/2026

AskBio

AskBio

501-1,000 employees

Clinical-stage gene therapy company developing AAVs

No salary listed

Research Triangle, Durham, NC, USA

In Person

Dual mentions RTP, NC and Durham, NC; primary location is RTP, NC per job description.

Category
People & HR (1)
Requirements
  • Bachelor’s degree in Human Resources, Business Administration, Communication or related field and 10+ years of progressive HR experience
  • HR Business Partner experience supporting complex technical or scientific organizations
  • Prior experience working in the pharmaceutical, biotech, CRO, CDMO or related industry
  • Demonstrated experience partnering with senior leaders on workforce planning, succession, and organizational design
  • Strong employee relations and judgment; comfortable navigating ambiguity and sensitive situations with discretion and confidence
  • Proven ability to operate at both strategic and tactical levels without losing effectiveness in either
  • Strategic mindset with operational bias; able to think long term while executing exceptionally well day to day
  • Executive presence; credible, confident, and able to influence senior scientific leaders
  • Strong interpersonal skills; builds trust quickly and sustains relationships across levels and disciplines
  • Comfort with complexity and pace; thrives in evolving, science driven environments
  • Data informed but human centered, balancing analytics with empathy and sound judgment
Responsibilities
  • Strategic Partnership & Leadership Advisory Serve as a trusted HR advisor and coach to senior leaders (SVP, VP, and Director level) within Therapeutics and R&D, providing counsel on organizational strategy, leadership effectiveness, and people related risk and opportunity
  • Partner with leaders to translate business and scientific strategy into people and organizational plans that support growth, innovation, and execution
  • Provide candid, data informed insight and challenge to leadership teams, helping them anticipate downstream workforce and organizational implications
  • Act as a strategic people advisor to the Therapeutics Leadership Team, bringing enterprise perspective, sound judgement, and constructive challenge to complex decisions impacting talent, culture, and organizational health
  • Workforce Planning & Organizational Design
  • Lead short and long term workforce planning for Therapeutics and R&D, aligning talent needs with pipeline priorities, program milestones, and budget realities
  • Partner on organizational design, role clarity, span and layer analysis, and operating model evolution to ensure the organization can scale effectively
  • Anticipate future capability gaps and partner with Talent, Learning, and TA to address them proactively
  • Ensure workforce and organizational decisions are governed through clear frameworks, tradeoffs, and leadership accountability, aligned with enterprise workforce strategy
  • Succession & Talent Management
  • Lead talent reviews and succession planning for critical scientific and leadership roles, ensuring robust pipelines and development plans
  • Partner with leaders on performance management, assessment, and development of both people managers and individual contributors in highly specialized scientific roles
  • Identify and address retention risks in critical talent populations
  • Own the end-to-end integration of core people processes for the Therapeutics leadership population (e.g., talent reviews, succession, rewards, promotion cycles), ensuring clarity of expectations, consistency of application, and disciplined execution across the leadership team
  • Manager & Employee Support (Hands On)
  • Provide day to day HR partnership to leaders and managers, including employee relations, performance concerns, team dynamics, and change management
  • Support leaders through complex situations with empathy, clarity, and consistency, ensuring alignment with company values and policies
  • Be visible and accessible at the RTP site, building trust and credibility with leaders and employees
  • Serve as a coach to senior leaders on people leadership—strengthening judgement, consistency, and confidence in managing performance, behavior, communication, and change
  • Change Management & Culture
  • Lead people side planning and execution for organizational changes, including restructures, leadership transitions, and priority shifts within the portfolio
  • Reinforce a culture of accountability, inclusion, and continuous learning within scientific teams
  • Partner with leaders to drive engagement and translate survey insights into action
  • Risk, Compliance & Governance
  • Act as a steward of people risk, compliance, and governance for Therapeutics & R&D
  • Provide clear guardrails and guidance on sensitive matters including performance management, investigations, off boarding, references, data access, and confidentiality
  • Partner closely with Legal and People & Culture Operations to mitigate legal, reputational, and cultural risk while enabling sound and timely leadership decisions
  • Collaboration Across HR
  • Work in close partnership with HR Centers of Excellence (Talent, Rewards, Learning & Development, Inclusion & Engagement) and HR Operations to ensure seamless employee experience and effective program delivery
  • Champion clarity of roles between HRBPs, COEs, and Operations, ensuring HR capacity is focused on highest impact work
Desired Qualifications
  • Advanced degree (MBA, MS) in related field
  • Prior experience supporting R&D, Therapeutics, or other highly technical functions in biotech, pharma, or life sciences

AskBio focuses on developing adeno-associated virus (AAV) gene therapies for genetic and complex disorders. Therapies use AAV vectors to deliver therapeutic DNA into patients’ cells, advancing from research and preclinical work through clinical trials toward commercialization. Its differentiation comes from a clinical-stage portfolio, in-house R&D, and partnerships that emphasize collaboration and shared development. Its goal is to bring gene therapies to patients with unmet medical needs by validating therapies clinically and pursuing strategic collaborations for commercialization.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$4.2B

Headquarters

Durham, North Carolina

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Bayer ownership funds global facilities in RTP, Edinburgh, and San Sebastian.
  • Phase 2 GenePHIT trial for AB-1002 completes enrollment in 2026.
  • Licenses to Pfizer, Takeda, Novartis validate platform technology.

What critics are saying

  • GenePHIT trial fails primary endpoint, halts AB-1002 program.
  • AB-1005 Phase 2 shows no GDNF increase, cancels Parkinson's advancement.
  • Bayer divests AskBio after clinical failures within 18-24 months.

What makes AskBio unique

  • AskBio pioneers AAV gene therapies with Pro10 manufacturing and extensive capsid library.
  • Founders' research underpins first two FDA-approved gene therapies.
  • Pipeline targets heart failure, Parkinson's, MSA-P, Pompe, and Huntington’s diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at AskBio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Meal Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Pharma Press
Mar 25th, 2026
a-Klotho cell and gene therapy potential.

a-Klotho cell and gene therapy potential. 25 March 2026 Avaí Bio recently announced that it has initiated manufacturing of a master cell bank of genetically modified cells that overexpress the α-Klotho protein, working alongside joint venture partner Austrianova through their shared entity, Klothonova. A Master Cell Bank isn't a research milestone. It's a manufacturing milestone. It's the GMP-compliant, fully characterized starting material from which all working cell banks and final therapeutic products will be produced. It's the moment a cell therapy programme transitions from "we think this could work" to "we're building the production infrastructure to deliver it." There is a key 'master' protein in your body called α-Klotho. The scientific community has been quietly obsessed with it since a Japanese researcher named Makoto Kuro-O discovered in 1997 that mice without the Klotho gene aged rapidly and died young - and mice with extra Klotho lived 30% longer. Since then, the research has only gotten more compelling. Peer-reviewed studies have linked higher Klotho levels to reduced risk of Alzheimer's, certain cancers, cardiovascular disease, and kidney failure. Mayo Clinic research has connected declining Klotho to arterial stiffness and vascular calcification. And here's the part that makes this personal: natural α-Klotho levels drop by approximately 50% after age 40. The protein that protects your brain, your heart, and your kidneys starts disappearing right when you need it most. The question the biotech industry is now racing to answer is simple: can you put it back? The global cell therapy market has surpassed $8.2 billion in 2026. The broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035. And at the intersection of regenerative medicine and longevity science, a small biotechnology company just hit a manufacturing milestone that turns the Klotho thesis from laboratory theory into production reality. The Cell-in-a-Box(R) technology is the delivery mechanism that makes the whole approach viable. When you transplant therapeutic cells into a patient, the immune system typically destroys them within days. Austrianova's encapsulation technology protects the cells inside a porous capsule, allowing the cells to continuously produce and secrete the target protein - in this case, α-Klotho - while protecting the cells from immune rejection. It's backed by over 50 peer-reviewed publications and decades of development. Avaí Bio's dual-programme approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging the same Cell-in-a-Box(R) encapsulation technology. The addressable markets are enormous: Alzheimer's disease alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading cause of death globally, and kidney disease affects 850 million people worldwide.

ChemXpert
Apr 3rd, 2025
Bayer Heralds Pipeline Progress, Blockbuster Launches and Advanced

Through AskBio, a wholly owned subsidiary of Bayer, it is developing a gene therapy as a potential new approach for treating congestive heart failure.

AskBio
Nov 5th, 2024
Brain Neurotherapy Bio | AskBio

Brain Neurotherapy Bio, Inc (BNB) is pleased to announce its recent merger with Asklepios BioPharmaceutical, Inc (AskBio), a Bayer company.

BambuUP
Sep 25th, 2024
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

Belief BioMed to collaborate with AskBio to explore the potential of new gene therapies.

The Business Journals
Apr 9th, 2024
AskBio co-founder Jude Samulski steps down, successor named

As it advances its pipeline of gene therapies, AskBio is planning to expand in the Triangle, essentially doubling its local footprint by acquiring space in Morrisville on Airport Road.